Ardent Health, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Ardent Health, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.32B | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $5.97B | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $5.41B | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $5.13B | Feb 27, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $135.81M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $210.34M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $53.90M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $188.91M | Feb 27, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $470.51M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $315.03M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $221.70M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($38.36M) | Feb 27, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.29B | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $4.96B | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $4.73B | Feb 27, 2025 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.61B | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $3.43B | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $3.65B | Feb 27, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $1.13B | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $670.90M | Feb 27, 2025 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $879.45M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $852.08M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $844.70M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $844.70M | Feb 27, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $501.61M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $365.80M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $155.45M | Feb 27, 2025 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $709.60M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $556.79M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $437.58M | Feb 27, 2025 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | Mar 16, 2026 |
| FY2024 | Dec 31, 2024 | $1.11B | Feb 27, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 27, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 27, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 142.86M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 142.75M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |